Emmaus Swaps Sales Force for Royalties in a High-Stakes Financial Pivot

TORRANCE, CA – August 14, 2026 – Emmaus Life Sciences, the company behind the sickle cell disease treatment Endari®, today reported a dramatic financial turnaround, swinging from a significant loss to a $1.3 million net income in the second quarter. But this newfound profitability isn't the result of a surge in drug sales. Instead, it’s the first tangible outcome of a radical strategic overhaul: dismantling its own commercial infrastructure in North America and outsourcing it to a partner in exchange for upfront cash and a share of future revenue.

A Turnaround Engineered by Dealmaking

On the surface, the quarterly results from Emmaus (OTCQB: EMMA) paint a picture of resounding success. Net revenues skyrocketed 124% to $6.3 million compared to the same period last year, while operating expenses fell by nearly 30% to $2.1 million. This combination flipped the company’s operating results from a $0.4 million loss in Q2 2025 to a $3.8 million income in Q2 2026.

The architect of this transformation is a licensing and distribution agreement with NeoImmuneTech, Inc. (NIT), which became effective on May 15. The deal grants NIT exclusive rights to market and sell Endari® in the U.S. and Canada. In return, Emmaus received an upfront payment, a portion of which was recognized as revenue this quarter, and will continue to earn royalties on NIT's sales.

“We recognized a part of the upfront payment and royalties as revenue which resulted in a 124% increase in net revenues,” commented Willis Lee, Chairman and Chief Executive Officer of Emmaus, in the company’s official statement. He also highlighted the corresponding reduction in operating expenses, a direct result of transferring the company's U.S. sales force to NIT as part of the arrangement. This move reveals a fundamental shift in strategy: Emmaus is no longer in the business of direct-to-market sales in its largest territory. It is now a licensor, a partner relying on the commercial network of another company to generate its primary revenue stream.

Outsourcing the Commercial Backbone

The agreement with NIT is a textbook example of a small biopharmaceutical company making a critical choice between control and capital. By handing over the reins to Endari's commercialization in North America, Emmaus has effectively outsourced its most expensive operational component. The company is not only offloading the costs associated with maintaining a sales and marketing team but also transferring the complex logistical network required for distribution and reimbursement.

For NIT, a clinical-stage company focused on immunotherapy, the deal is equally strategic. It provides an opportunity to build a commercial backbone using an already-approved therapy. The infrastructure—from distribution channels to relationships with payers and providers—that NIT establishes for Endari® can later be leveraged to launch its own proprietary drugs, like its pipeline candidate NT-I7. It’s a symbiotic relationship where Emmaus gets a financial lifeline and a streamlined operational model, while NIT acquires a ready-made platform to enter the commercial market.

Under a related supply agreement, Emmaus will continue to manufacture Endari® and sell it to NIT at cost plus a double-digit percentage margin, ensuring another layer of revenue. This new architecture transforms Emmaus from a vertically integrated biopharma into a leaner entity focused on manufacturing, regulatory affairs, and managing its global partnerships.

The Lingering Shadow of Debt

While the NIT deal provides a crucial injection of cash and a path to quarterly profits, it does not erase the significant financial headwinds Emmaus faces. A deeper look at the company’s balance sheet reveals a precarious position that this single deal, however positive, cannot entirely solve. As of June 30, the company reported a staggering stockholders' deficit of $66.2 million and total liabilities of $82.5 million, dwarfing its total assets of $16.4 million.

Most concerning is the "going concern" warning present in its financial filings, a formal declaration that there is "substantial doubt about its ability to continue as a going concern." This is not a new development; the auditor's report for 2025 carried the same warning, underscoring a persistent reliance on raising new capital and restructuring debt to simply stay afloat. With current liabilities of $66.1 million set against just $6.0 million in current assets, the company's short-term financial health remains under intense pressure.

Furthermore, the company has significant convertible notes on its books. These notes represent a potential dilution of 50.8 million shares, which would dramatically increase the 70.2 million shares currently outstanding. For investors celebrating the quarterly profit, this overhang represents a future risk to the value of their holdings. The strategic pivot, therefore, is less a final victory and more a calculated maneuver to buy time and create breathing room to address these deeper structural challenges.

A New Global Strategy for a Niche Therapy

The decision to license out Endari® in North America is also driven by the evolving competitive landscape. The drug's U.S. orphan exclusivity expired in July 2024, opening the door to generic competition for its L-glutamine formulation. In this environment, competing on price and market access requires a robust and well-funded commercial operation—a battle Emmaus has wisely chosen to sidestep by partnering with NIT.

This strategic retreat from the front lines in its home market allows Emmaus to redeploy its limited resources toward what management identifies as higher-growth regions. The company is actively pursuing expansion in the Middle East, Brazil, and Europe. It has already secured market exclusivity and approvals across several nations in the Middle East and North Africa (MENA), including the UAE, Qatar, and Saudi Arabia. This global diversification strategy relies on building a network of international partners, transforming Emmaus into a hub that manages a portfolio of regional commercialization efforts rather than executing them all itself.

For the approximately 100,000 people in the United States living with sickle cell disease, the key question is whether this new arrangement will improve or impede access to Endari®. By placing the therapy in the hands of a partner building its commercial presence, the hope is that a focused effort will maintain, if not expand, the drug's reach. The success of this partnership will be the ultimate test of whether outsourcing the commercial network was the right move for the company, its investors, and the patients who depend on its therapy.